Solaymani-Dodaran: Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia

Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia

Solaymani-Dodaran et al., International Immunopharmacology, doi:10.1016/j.intimp.2021.107522

Solaymani-Dodaran et al., Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia, International Immunopharmacology, doi:10.1016/j.intimp.2021.107522

Mar 2021 Source PDF

Twitter
Facebook

All Studies Meta

RCT late stage patients (median SpO₂ 89), 193 treated with favipiravir, 187 with lopinavir/ritonavir, showing no significant differences in mortality, intubation, or ICU admission.

Important missing comments or errors? Let us know.

risk of death, 19.2% higher, RR 1.19, p = 0.54, treatment 26 of 190 (13.7%), control 21 of 183 (11.5%).

risk of mechanical ventilation, 53.0% higher, RR 1.53, p = 0.15, treatment 27 of 190 (14.2%), control 17 of 183 (9.3%).

risk of ICU admission, 19.4% higher, RR 1.19, p = 0.56, treatment 31 of 190 (16.3%), control 25 of 183 (13.7%).

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Solaymani-Dodaran et al., 11 Mar 2021, Randomized Controlled Trial, Iran, peer-reviewed, 44 authors, this trial compares with another treatment - results may be better when compared to placebo.

All Studies Meta Analysis Submit Updates or Corrections

This Paper Favipiravir All

Abstract: International Immunopharmacology 95 (2021) 107522 Contents lists available at ScienceDirect International Immunopharmacology journal homepage: www.elsevier.com/locate/intimp Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia Masoud Solaymani-Dodaran a, b, c, Mostafa Ghanei d, *, Mehdi Bagheri e, Ali Qazvini f, Ensieh Vahedi g, Seyed Hassan Saadat h, Seyed Amin Setarehdan i, j, Akram Ansarifar k, Hossein Biganeh l, Arash Mohazzab m, n, Davood Khalili o, Amir Hosein Ghazale p, Mohammad Reza Heidari q, Ali Taheri r, Maliheh Khoramdad s, Mohammad Mahdi Asadi t, Masoud Nazemieh u, Mojtaba Varshochi v, Samaneh Abbasian w, Ali Bakhtiari x, Reza Mosaed y, Seyyed-Javad Hosseini-shokouh z, Masoume Shahrokhi aa, Zeynab Yassin ab, Mohammad Ali Zohal ac, Maryam Qaraati ad, Nafiseh Rastgoo ae, Ramin Sami af, Mohammad Javad Eslami ag, Akram Asghari ah, Mansoor Namazi ai, Shadi Ziaie aj, Raana Jafari-Moghaddam ak, Saeid Kalantari al, Mohammad Memarian am, Javad Khodadadi an, Mohammad Hossein Afshari ao, Mansooreh Momen-Heravi ap, Niusha Behzadseresht aq, Ahmad Reza Mobayen ar, Abolfazl Mozafari as, Fatemeh Movasaghi at, Maryam Haddadzadeh Shoushtari au, Javad Moazen av a Minimally Invasive Surgery Research Center, Hazrat-e-Rasool Hospital, Iran University of Medical Science, Tehran, Iran Division of Epidemiology and Public Health, University of Nottingham, Nottingham, NG7 2UH, UK c School of Public Health, Iran University of Medical Science, Tehran, Iran d Chemical Injuries Center, Systems Biology and Poisoning Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran e Health Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran f Trauma Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran g Chemical Injuries Research Center, Systems Biology and Poisoning Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran h Behavioral sciences research center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran i Minimally Invasive Surgery Research Center, Hazrat-e-Rasool Hospital, Iran University of Medical Science, Tehran, Iran j School of Public Health, Iran University of Medical Science, Tehran, Iran k School of Public Health, Iran University of Medical Science, Tehran, Iran l Student Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran m School of Public Health, Iran University of Medical Science, Tehran, Iran n Reproductive Biotechnology Research Center, Avicenna Research Institute Tehran, ACECR, Tehran, Iran o Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran p Student Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran q Student Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran r Student Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran s School of Public Health, Iran University of Medical Science, Tehran, Iran t Student Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran u Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Science, Tabriz, Iran v Infectious and Tropical Disease Research Center, Tabriz University of Medical Science, Tabriz, Iran w Liver and Gastrointestinal Disease Research Center, Tabriz University of Medical Science, Tabriz,..

Late treatment
is less effective

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit